| Document Date: 2015-03-26 19:23:33
Open Document File Size: 231,51 KBShare Result on Facebook
Company IgG / ADP / Ames / ESPRIT / Merck Sharp & Dohme Corp. / Merck & Co. Inc. / / Event FDA Phase / / Facility IIIa complex / / IndustryTerm arterial access site / Treatment of acute coronary syndrome / / MedicalCondition strokes / lymphoma / pulmonary hemorrhage / intracranial hemorrhage / immune-mediated thrombocytopenia / anaphylaxis / Thrombocytopenia / Known hypersensitivity / unstable angina / injury / hemorrhagic stroke / hematemesis / Hypersensitivity / Myocardial Infarction Study group / dissociation / hypotension / cerebral infarction / dyspnea / hematuria / Carcinogenesis / Stroke / Acute profound thrombocytopenia / acute coronary syndrome / Severe hypertension / Severe uncontrolled hypertension / renal insufficiency / myocardial infarction / urticaria / coronary artery disease / decreased muscle tone / coronary thrombosis / thrombosis / Syndrome / disorders / / MedicalTreatment platelet transfusions / Angioplasty / cardiac catheterization / intravenous infusion / surgery / thrombolytic therapy / catheters / bypass / Major surgery / autotransfusion / renal dialysis / dialysis / / Organization DOSAGE AND ADMINISTRATION / FDA / Administration of INTEGRILIN / / Person Spike / / / Position Major / forward / / Product potassium chloride / dextrose / nitroglycerin / INTEGRILIN / lidocaine / atropine / adenosine / furosemide / / ProvinceOrState Michigan / / Technology antibodies / Pharmacokinetics / Pharmacodynamics / dialysis / / URL www.fda.gov/medwatch / /
SocialTag |
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INTEGRILIN safely and effectively. See full prescribing information for INTEGRILIN. ®